Humana Inc. (HUM) Price Target Cut to $246.00

Humana Inc. (NYSE:HUM) had its price target cut by Credit Suisse Group from $256.00 to $246.00 in a research report released on Friday morning. They currently have a neutral rating on the insurance provider’s stock.

Several other equities analysts have also weighed in on the stock. BMO Capital Markets lifted their target price on shares of Humana from $290.00 to $300.00 and gave the company an outperform rating in a report on Friday. Morgan Stanley reduced their target price on shares of Humana from $276.00 to $270.00 and set an overweight rating on the stock in a report on Thursday, November 9th. Royal Bank Of Canada restated a sector perform rating and set a $242.00 target price (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Zacks Investment Research lowered shares of Humana from a strong-buy rating to a hold rating in a report on Tuesday, October 17th. Finally, Jefferies Group LLC restated a hold rating and set a $257.00 target price on shares of Humana in a report on Friday, October 13th. Thirteen analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $252.81.

Shares of Humana (NYSE HUM) traded down $3.45 during midday trading on Friday, hitting $240.94. 1,445,100 shares of the stock traded hands, compared to its average volume of 1,376,997. Humana has a one year low of $186.25 and a one year high of $264.56. The stock has a market cap of $34,913.58, a PE ratio of 20.85, a PEG ratio of 1.68 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.18 EPS. sell-side analysts forecast that Humana will post 11.64 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Humana Inc. (HUM) Price Target Cut to $246.00” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/11/14/humana-inc-hum-price-target-cut-to-246-00.html.

The business also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.66%. Humana’s dividend payout ratio (DPR) is presently 12.59%.

In related news, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Timothy S. Huval sold 7,803 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $258.14, for a total transaction of $2,014,266.42. Following the sale, the vice president now directly owns 8,831 shares of the company’s stock, valued at approximately $2,279,634.34. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,660 shares of company stock worth $5,319,600. Company insiders own 0.80% of the company’s stock.

Several large investors have recently made changes to their positions in HUM. Janus Henderson Group PLC grew its position in shares of Humana by 7,848.8% during the 2nd quarter. Janus Henderson Group PLC now owns 1,567,587 shares of the insurance provider’s stock valued at $377,192,000 after buying an additional 1,547,866 shares during the last quarter. FMR LLC grew its position in shares of Humana by 29.3% during the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock valued at $1,571,264,000 after buying an additional 1,479,210 shares during the last quarter. Koch Industries Inc. bought a new stake in shares of Humana during the 2nd quarter valued at about $404,000. Acadian Asset Management LLC grew its position in shares of Humana by 1,340.0% during the 2nd quarter. Acadian Asset Management LLC now owns 420,578 shares of the insurance provider’s stock valued at $101,199,000 after buying an additional 391,372 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in shares of Humana by 39.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,358,617 shares of the insurance provider’s stock valued at $326,910,000 after buying an additional 386,162 shares during the last quarter. 96.15% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply